Gilead Sciences Inc. (GILD)
NASDAQ
Real-time Data
01:30 PM
Day's Range
145.6052 wk Range
108.46Overview - GILD - Gilead Sciences Inc.
Key Statistics
Valuation
Enterprise Value
202.46B
P/E (Trailing)
‪17.86‬
P/E (Forward)
‪14.77‬
PEG Ratio
‪-0.02‬
Price / Sales (TTM)
‪5.94‬
Price / Book
‪15.32‬
EV / EBITDA
‪13.86‬
Profitability
Gross Margin
‪79.76%‬
Profit Margin
‪-10.63%‬
Operating Margin
‪33.67%‬
Return on Assets
‪14.08%‬
Return on Equity
‪-20.68%‬
Ownership
Shares Outstanding
1.24B
Float
1.23B
Short % of Shares Outstanding
‪1.97%‬
Held by Insiders
‪0.11%‬
Held by Institutions
‪92.27%‬
Price stats
Beta
‪0.33‬
50-Day Avg
‪131.90‬
200-Day Avg
‪133.06‬
Dividends
Payout Ratio
‪43.40%‬
Frequency
Quarterly
Analyst Consensus
29 analysts
Average price target
‪$ 157.41‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GILD - Gilead Sciences Inc.
Peers - GILD - Gilead Sciences Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on NASDAQ.
- GILDNASDAQGilead Sciences Inc.184.46BMarket Cap+22.87%52-week change17.87P/E (Trailing)‪-10.63%‬Profit Margin
- AZNNASDAQAstraZeneca PLC American Depositary Shares263.12BMarket Cap+5.63%52-week change25.33P/E (Trailing)‪17.02%‬Profit Margin
- AMGNNASDAQAmgen Inc.239.08BMarket Cap+34.88%52-week change27.55P/E (Trailing)‪22.95%‬Profit Margin
- SNYNASDAQSanofi American Depositary Receipt110.27BMarket Cap-8.89%52-week change24.26P/E (Trailing)‪8.09%‬Profit Margin
- ROPNASDAQRoper Technologies Inc.41.09BMarket Cap-26.22%52-week change17.15P/E (Trailing)‪30.24%‬Profit Margin
- BIIBNASDAQBiogen Inc.32.22BMarket Cap+37.32%52-week change38.44P/E (Trailing)‪8.32%‬Profit Margin
- GRFSNASDAQGrifols, S.A. American Depositary Receipt5.43BMarket Cap-22.46%52-week change10.39P/E (Trailing)‪6.09%‬Profit Margin
Profile Summary - GILD - Gilead Sciences Inc.
About
Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases. The company’s core franchise centers on therapies for HIV and viral hepatitis, including hepatitis B and C, where its antiviral portfolio…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
